Analysts Anticipate Nightstar Therapeutics PLC (NITE) to Announce -$0.39 Earnings Per Share

Equities research analysts expect Nightstar Therapeutics PLC (NASDAQ:NITE) to report earnings of ($0.39) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Nightstar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.33). The business is expected to issue its next quarterly earnings results on Monday, November 12th.

On average, analysts expect that Nightstar Therapeutics will report full-year earnings of ($1.59) per share for the current year, with EPS estimates ranging from ($1.77) to ($1.42). For the next financial year, analysts expect that the company will report earnings of ($1.60) per share, with EPS estimates ranging from ($1.94) to ($1.38). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Nightstar Therapeutics.

Nightstar Therapeutics (NASDAQ:NITE) last posted its quarterly earnings data on Monday, August 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.12.

Several brokerages recently weighed in on NITE. Leerink Swann increased their target price on Nightstar Therapeutics from $30.00 to $35.00 and gave the stock a “positive” rating in a research report on Monday, September 24th. BMO Capital Markets set a $41.00 target price on Nightstar Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 24th. Mizuho increased their target price on Nightstar Therapeutics to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, September 4th. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Nightstar Therapeutics in a research report on Tuesday, September 25th. Finally, Janney Montgomery Scott began coverage on Nightstar Therapeutics in a research report on Wednesday, August 22nd. They issued a “buy” rating and a $34.00 target price on the stock. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $33.25.

Shares of NITE traded up $0.17 during trading hours on Friday, hitting $14.19. The stock had a trading volume of 162,252 shares, compared to its average volume of 74,674. The firm has a market capitalization of $574.08 million and a P/E ratio of -8.71. Nightstar Therapeutics has a 12-month low of $10.01 and a 12-month high of $29.55.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Redmile Group LLC increased its position in shares of Nightstar Therapeutics by 0.9% during the second quarter. Redmile Group LLC now owns 1,785,446 shares of the company’s stock worth $28,567,000 after acquiring an additional 16,500 shares during the last quarter. Partner Fund Management L.P. grew its stake in Nightstar Therapeutics by 0.7% in the second quarter. Partner Fund Management L.P. now owns 1,016,980 shares of the company’s stock worth $16,272,000 after purchasing an additional 7,007 shares in the last quarter. Woodford Investment Management Ltd acquired a new position in Nightstar Therapeutics in the second quarter worth about $5,024,000. Millennium Management LLC acquired a new position in Nightstar Therapeutics in the first quarter worth about $507,000. Finally, Stanley Laman Group Ltd. acquired a new position in Nightstar Therapeutics in the second quarter worth about $195,000. 28.62% of the stock is currently owned by institutional investors and hedge funds.

About Nightstar Therapeutics

Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy.

See Also: Risk Tolerance

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply